Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

5 Pages (Click to Jump) V   1 2 3 4 > » 

Verharven
Posted on: Mar 31 2020, 12:43 PM


Group: Member
Posts: 851

Now up to number 8 on the most shorted list at 9.58% - go CUV!!!
  Forum: By Share Code

Verharven
Posted on: Mar 30 2020, 12:26 PM


Group: Member
Posts: 851

Shorts still on the up, to now 9.31% which is an ATH and for the first time, we've hit the Top 10 with CUV now the tenth most shorted stock on the ASX
  Forum: By Share Code

Verharven
Posted on: Mar 25 2020, 05:06 AM


Group: Member
Posts: 851

Some pretty insane volume on CLVLY. I just looked at the last 5 years data and at a volume of 148k as I write this, is the second highest on record with the only day above this being FDA approval day at 210k. At USD11.02 currently which is AUD18.64.
  Forum: By Share Code

Verharven
Posted on: Mar 23 2020, 10:11 AM


Group: Member
Posts: 851

So from my reading of this, is it realistic that patients could start accessing Scennesse from the three centres already online from mid April?
  Forum: By Share Code

Verharven
Posted on: Mar 19 2020, 10:53 AM


Group: Member
Posts: 851

Newsletter out


Attached File(s)
Attached File  Announcements.pdf ( 573.55K ) Number of downloads: 217

 
  Forum: By Share Code

Verharven
Posted on: Mar 16 2020, 02:18 PM


Group: Member
Posts: 851

UniSuper stops loans to short sellers

One of Australia’s largest superannuation funds, the $85 billion UniSuper fund, has pulled the pin on lending its stock to short-sellers as markets plunge.

UniSuper, which manages the savings of university staff members told its custodian, BNP Paribas Securities Services, to suspend its stock lending program effective immediately.

BNP Paribas will also recall all shares currently out on loan, without exception.

UniSuper chief investment officer John Pearce said: “In a normally functioning market we’re comfortable lending our shares as we genuinely believe that it adds to market efficiency.”

“The ability to short-sell adds to liquidity and price discovery in an orderly market. However, we are now in a market gripped by panic and we believe that restricting the ability to short-sell is in the best interest of promoting a more orderly market.”

“We are only one fund and the efficacy of our actions will depend on how many other funds follow a similar path. Of course, we are not privy to the thinking of other funds who lend their stock.”

The program will be suspended indefinitely.

https://www.theaustralian.com.au/business/m...ec182f513c6c142
  Forum: By Share Code

Verharven
Posted on: Mar 11 2020, 05:40 PM


Group: Member
Posts: 851

Here's the aftermarket trading

LT XT = Late Trade Crossing Trade
SX XT = Portfolio Special Crossing Trade


Attached thumbnail(s)
Attached Image



 
  Forum: By Share Code

Verharven
Posted on: Mar 5 2020, 07:42 AM


Group: Member
Posts: 851

FYI for YouTube videos, you can turn on subtitles with automatic language translation as quite a few German ones posted. The translation is never perfect as is happening on the fly from the audio, but pretty good to work out what is happening in real-time.
  Forum: By Share Code

Verharven
Posted on: Mar 5 2020, 04:58 AM


Group: Member
Posts: 851

Yes, that was based on the information being posted on FB as actually being true - which I have serious doubts about
  Forum: By Share Code

Verharven
Posted on: Mar 5 2020, 03:53 AM


Group: Member
Posts: 851

You can't sign up patients to a trial that you don't have ethical approval to run in the first place - you would be shut down in an instant. Patients need to be provided with trial details in a plain language statement which also includes ethics approval and contact details as such so that they can provide informed consent. Also, any patient is free to leave the trial at any stage for whatever reason they like - they aren't really 'locked in'.
  Forum: By Share Code

Verharven
Posted on: Mar 4 2020, 07:30 PM


Group: Member
Posts: 851

Probably would want to see some additional verification of this. They only put out a release on the P2 results in November of last year, but somehow since then have designed the study, got all the treating centres set up and importantly, got all the required institutional ethics in place to recruit in April? Ethics approval alone does not work on those sorts of timelines with so many sites involved - happy to shown wrong on this, but it is pretty amazing if that has happened. And importantly, no mention of it on the Clinical Trials database https://clinicaltrials.gov/ct2/results?cond...city=&dist=
  Forum: By Share Code

Verharven
Posted on: Mar 4 2020, 04:42 AM


Group: Member
Posts: 851

Well, it's rare that I'm pleasantly surprised about CUV as could just see the US Scenesse site sitting in maintenance mode for months, but there it is up and running. Sure, it isn't going to win any design awards, but seems functional and fairly well presented to me. And great to see the 3 current EPP centres of Miami, LA and Detroit actually listed. And meanwhile, on the German and US exchanges, CUV Is trading above AUD20
  Forum: By Share Code

Verharven
Posted on: Mar 3 2020, 09:13 AM


Group: Member
Posts: 851

FDA confirms Type C meeting for vitiligo for 29 April

Attached File(s)
Attached File  Announcements.pdf ( 185.6K ) Number of downloads: 95

 
  Forum: By Share Code

Verharven
Posted on: Mar 3 2020, 07:51 AM


Group: Member
Posts: 851

"Maintenance Mode" - just oozes professionalism
  Forum: By Share Code

Verharven
Posted on: Mar 2 2020, 06:59 PM


Group: Member
Posts: 851

Up to about AUD19 on very good volume - sorely needed!
  Forum: By Share Code

Verharven
Posted on: Mar 2 2020, 12:24 PM


Group: Member
Posts: 851

Again, why do you have Tom Petrosky's picture there???
  Forum: By Share Code

Verharven
Posted on: Feb 28 2020, 05:41 PM


Group: Member
Posts: 851

Why have you put Tom Petrosky's photo on this?
  Forum: By Share Code

Verharven
Posted on: Feb 28 2020, 09:51 AM


Group: Member
Posts: 851

And add to that data for inclusion and exclusion is based on 6-months average of SP and volume - will be a long time yet before exclusion discussions are warranted.
  Forum: By Share Code

Verharven
Posted on: Feb 11 2020, 02:33 PM


Group: Member
Posts: 851

NEA shorting has finally broken with CUV and it was the earnings guidance downgrade that saw the SP crash 25% that was the catalyst for shorters to start closing out. Maybe they're waiting for a similar style of event with CUV as their trigger to exit. Us CUV longs are made of sturdier stuff than that to turn us into bed wetters, what with the constant disappointment with the very odd bright ray the norm for years upon years.
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Feb 3 2020, 09:05 AM


Group: Member
Posts: 851

Australia is not the US or Europe. The key factor is being listed on the PBS (Pharmaceutical Benefits Scheme) so the Government covers most of the cost under the public health system of Medicare. If not on the PBS, then the patient would have to pay. Most medicines in Australia are on the PBS.
  Forum: By Share Code

Verharven
Posted on: Jan 30 2020, 03:19 PM


Group: Member
Posts: 851

Billy, if you're a holder of the stock unless you've got some next-level CGT issues to balance out, you sell it, you don't pay price premiums to borrow the stock from a broker to short it
  Forum: By Share Code

Verharven
Posted on: Jan 30 2020, 12:51 PM


Group: Member
Posts: 851

Shorts up to 7.99% and now at position 22 of the most shorted stocks. A salutary tale for NEA whose short activity (12.05% and position 7) has paralleled CUV since ASX200 inclusion and today issued a profit guidance downgade - SP down 25% - shorters popping champagne corks.
  Forum: By Share Code

Verharven
Posted on: Jan 15 2020, 06:41 PM


Group: Member
Posts: 851

CUV is now the 27th most shorted stock on the ASX at 7.39%. You'd have to say the SP is doing a sterling job in the face of all this shorting with the SP staying pretty well flat for some time. Won't be flat when the shorters have to buy back in.
  Forum: By Share Code

Verharven
Posted on: Jan 15 2020, 04:59 PM


Group: Member
Posts: 851

"With registration dossier submitted @ 23/12/2019 (assuming accepted by the TGA), we should expect before the last week of May 2020 approval."

The review process is 150 working days so that's about 7.5 months so late August at the earliest
  Forum: By Share Code

Verharven
Posted on: Jan 13 2020, 12:25 PM


Group: Member
Posts: 851

From Silverchair on Hotcopper

"Broker Moelis Australia has upgraded its price target for Clinuvel today - Target Price of $44.42. The truth is without the enormous amount of artificial selling via shorts in the last 6 months the CUV share price would already be at $44. The shorting is good in that it has allowed me to buy a lot more shares at bargain basement prices so thanks for that! Going to be a big couple of years for CUV IMO.."
  Forum: By Share Code

Verharven
Posted on: Dec 23 2019, 09:03 AM


Group: Member
Posts: 851

Wow - they announced the TGA registration pathway on Oct 30 with a planned submission for Q1 2020 which if it was done by March 31 I would have been pretty stunned. So for the first time ever in the history of CUV, they've smashed their deadlines. Nice one. Please, more of this. Now the clock is ticking for 150 working days to assess.
  Forum: By Share Code

Verharven
Posted on: Dec 21 2019, 09:02 AM


Group: Member
Posts: 851

Database errors on the Shortman website for the last few days. Can always view the current aggregate short positions directly from the ASIC website here https://asic.gov.au/regulatory-resources/ma...-reports-table/

Open short positions for CUV as of Monday 16 December stands at 6.9%
  Forum: By Share Code

Verharven
Posted on: Dec 11 2019, 05:38 PM


Group: Member
Posts: 851

Here's the trade


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Dec 4 2019, 06:08 PM


Group: Member
Posts: 851

LH has now been banned. He/she is now moaning about it over on the Yahoo! CLVLY discussion group. We get it, we all agree MT-7117 is something we all need to keep a watch on as it develops but can do without the endless repetition of the same points and God complex attitude that you're the only bearer of the true facts.
  Forum: By Share Code

Verharven
Posted on: Dec 2 2019, 08:52 AM


Group: Member
Posts: 851

Would want to be some amazing Phase II results to give them confidence there will be greater efficacy and less toxicity than Scenesse to warrant a Phase III
  Forum: By Share Code

Verharven
Posted on: Nov 27 2019, 07:30 AM


Group: Member
Posts: 851

What hasn't been mentioned about MT-7117 is the courageous assumption that the FDA would only require one Phase III trial - normally two are needed which puts the timelines for even the possibility of it being a competitor out to 5 years. Even PW stated they are preparing for likely two P3s for vitiligo and this for an approved drug with an impeccable safety profile.
  Forum: By Share Code

Verharven
Posted on: Nov 26 2019, 03:21 PM


Group: Member
Posts: 851

If you had EPP and were in the US and had an insurer ready to pay for Scennesse, why on earth would anyone agree to forgo that and instead participate in a clinical trial of another drug in development where the efficacy (and safety) is still being worked out and also bearing the risk if they did go in the trial, could be in the placebo group? What am I missing here that CUV will somehow lose potential sales for the period the enrolment in the trial was happening? Sure, if you had no way to pay for Scennesse, you'd consider the trial, but that person would never have been a customer for CUV in the first place.
  Forum: By Share Code

Verharven
Posted on: Nov 23 2019, 02:17 PM


Group: Member
Posts: 851

If you're after some leveraged long exposure to CUV that is tradeable on the open market, then CitiFirst has just released 4 warrants (American style which means that they can be exercised to buy the underlying shares if you so desire) with strike prices following and no expiry date. I can see all of them on my broking platform though only CUVKOA has had any trading action since their release on November 5 for a grand total of 10k warrants (1 x multiplier).


CUVKOA $23.541 https://au.citifirst.com/EN/Products/MINIs/...HARMLTD/CUVKOA/
CUVKOB $21.97 https://au.citifirst.com/EN/Products/MINIs/...HARMLTD/CUVKOB/
CUVKOC $19.18 https://au.citifirst.com/EN/Products/MINIs/...HARMLTD/CUVKOC/
CUVKOD $17.435 https://au.citifirst.com/EN/Products/MINIs/...HARMLTD/CUVKOD/
  Forum: By Share Code

Verharven
Posted on: Nov 22 2019, 12:07 PM


Group: Member
Posts: 851

"With PW being such a massive shareholder this SP manipulation situation would obviously be concerning to him also yes?"

A direct question to PW at the AGM was about the shorting and he gave a very frank answer which I'll paraphrase: "As an MD, it is of no concern. As a shareholder, it is of concern to me" He also said after that everyone who bet against CUV in the past has lost - fair call I say.
  Forum: By Share Code

Verharven
Posted on: Nov 12 2019, 03:45 AM


Group: Member
Posts: 851

"MT-7117 was generally well tolerated with an acceptable safety profile."

While we'll have to wait until 2020 to see the results, this language while potentially being ultra-conservative, is not the sort of language I'm used to seeing for something that has little to minimal side-effects with the use of the words 'generally' and 'acceptable'.
  Forum: By Share Code

Verharven
Posted on: Nov 10 2019, 08:21 AM


Group: Member
Posts: 851

Is there really a need for the personal attack on another poster? Play the ball, not the man okay Ian?
  Forum: By Share Code

Verharven
Posted on: Oct 30 2019, 11:36 AM


Group: Member
Posts: 851

TGA grants priority review for registration pathway. The dossier to be submitted Q1 2020 (I'll believe that when I see it) with TGA review to take ~7 months (150 working days). It is pleasing to see action pretty quickly on this however so soon post FDA decision.


Attached File(s)
Attached File  Announcements.pdf ( 168.81K ) Number of downloads: 120

 
  Forum: By Share Code

Verharven
Posted on: Oct 30 2019, 11:03 AM


Group: Member
Posts: 851

Letter from the incoming chair: please vote for the performance rights. Thinking they've been getting a lot of push back and votes may not be a certainty.

Attached File(s)
Attached File  Announcements.pdf ( 108.83K ) Number of downloads: 85

 
  Forum: By Share Code

Verharven
Posted on: Oct 29 2019, 03:08 AM


Group: Member
Posts: 851

Thank you! I noticed the absence of daily gross shorts a few days ago and wondered why. ASX 'owns' this data so clearly don't want to let others use it so you have to now manually check this each day if you want from here https://www.asx.com.au/data/shortsell.txt

ASIC though 'own' the aggregated data which lags by 4 trading days which is what Shortman publishes still and is the most relevant information anyway. The data comes from here https://asic.gov.au/regulatory-resources/ma...-reports-table/
  Forum: By Share Code

Verharven
Posted on: Oct 29 2019, 03:02 AM


Group: Member
Posts: 851

Here's the graph (the one on the left obviously!) and of course this is average data for many company data point so no expectation that CUV must perfectly track this. The absence of a run up in price to approval day was from shorting. But yes, a decline in the weeks after approval is pretty normal - CUV's is much larger because of the initial approval spike, but the direction is the same as the average.


Attached image(s)
Attached Image

 
  Forum: By Share Code

Verharven
Posted on: Oct 28 2019, 07:32 AM


Group: Member
Posts: 851

I voted through Computershare and was simple as the option was there as I'm already a registered user of the platform so can do all the admin of my shares within it.
  Forum: By Share Code

Verharven
Posted on: Oct 25 2019, 03:40 PM


Group: Member
Posts: 851

On a feeling, thought I'd check back into the trading after the market close at 4:10 pm and what do you know - another 150k in a cross trade well after the close



Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Oct 24 2019, 06:31 PM


Group: Member
Posts: 851

I had to go into the course of sales to see it as very rare to see an aftermarket trade go through and not something I ever check on after the trading is done at 4:10 pm. Note the error in the price Farleap11 gave as should be $30.40. You can see the volume reflected in the quote CUV have on their site as the volume they always give is for the ASX and Chi-X combined so 470k shares for the day with 460k of that on the ASX. https://www.clinuvel.com/investors/share-prices

S3 XT is a Block Special Crossing which basically means it's a special sized (usually large) cross trade



Attached thumbnail(s)
Attached Image



 
  Forum: By Share Code

Verharven
Posted on: Oct 23 2019, 04:50 PM


Group: Member
Posts: 851

Receipts were $10.7M for this quarter last year and $5.6M for the same quarter the year before. I'm going for a number of $15.2M
  Forum: By Share Code

Verharven
Posted on: Oct 19 2019, 04:30 AM


Group: Member
Posts: 851

I agree with your post about potentially accelerated approval for XP, though this part is not entirely correct:

"If new clinical trials were unethical in EPP, I think clinical trials in XP would be even more unethical, since a randomized placebo controlled trial would cause cancerous lesions and great pain among the patients in the placebo arm."

When there is no effective treatment for a condition, a placebo is completely ethical to use as you still need to determine if the new intervention is effective so in this case, the placebo represents current best-practice treatment. There have been some cases where these sort of clinical trials have been shown to be so effective mid-trial that they were stopped as to continue on with a placebo group would be unethical. If there was already a drug treatment then this would be the standard of care for the placebo group (so they would still get a dummy implant) that Scenesse would be compared to. This is called a comparator study. If the current treatment was withheld this would be unethical and likely never approved by an ethics board.
  Forum: By Share Code

Verharven
Posted on: Oct 18 2019, 04:45 PM


Group: Member
Posts: 851

Yes, the only growth has been in the 1-1,000 group so lots of retail small investors mopping up the crumbs from the bigger holders
  Forum: By Share Code

Verharven
Posted on: Oct 18 2019, 10:35 AM


Group: Member
Posts: 851

"On 31 May, the FDA used its discretionary tool to request a three month extension to the formal review user fee goal date, providing a new target date 6 October. We assessed the delay as a positive measure, since the Agency had had ample opportunity to reject the submission, issue a Refusal to File or even request a withdrawal. None of the events had occurred during our submission or review, and our teams kept working towards satisfying all outstanding questions from the agency."
  Forum: By Share Code

Verharven
Posted on: Oct 17 2019, 10:50 AM


Group: Member
Posts: 851

Newsletter out. I didn't realise they started issuing German communiques in May 2019 to cater for the large investment community there 👍👍


Attached File(s)
Attached File  Announcements.pdf ( 237.01K ) Number of downloads: 241

 
  Forum: By Share Code

Verharven
Posted on: Oct 16 2019, 03:13 PM


Group: Member
Posts: 851

You can always view short data yourself here https://www.shortman.com.au/stock?q=cuv

Went down 0.22 percentage points to now 5.58% for Thursday of last week when there were 160k gross shorts for the day so much more closing of open positions going on rather than opening new positions. Interesting the gross shorts really dropped off yesterday - down to 24k. So i'm seeing a very slow unwinding of shorts overall so SP drop probably more influenced by profit-taking I'd say - that's healthy..
  Forum: By Share Code

Verharven
Posted on: Oct 16 2019, 10:00 AM


Group: Member
Posts: 851

Try shorters, profit-takers (good luck to anyone that has cashed some in after such a long wait) and despite all the promo and exposure post FDA decision, people probably look at CUV without the in-depth understanding that most of us have and all they see is an expensive company (based on P/E) with a single drug and a tiny patient population so they haven't bought in..
  Forum: By Share Code

Verharven
Posted on: Oct 16 2019, 04:40 AM


Group: Member
Posts: 851

For the benefit of our overseas readers, the two recent interviews posted with Alan Kohler and Tom Pretosky are big 'known names' to the general public. These two guys have very high media profiles as they do daily financial reports on several of the main TV networks so PW has clearly come 'out of the shadows' and is shouting the CUV story to anyone and everyone. Please correct me too, but I believe Alan's Eureka report is one of the biggest subscription services around.
  Forum: By Share Code

Verharven
Posted on: Oct 15 2019, 01:45 PM


Group: Member
Posts: 851

CommSec's Tom Petrosky interviews PW - can't fault him for the promo work he's doing post-approval.

https://www.youtube.com/watch?v=39O8oxM1Cn8
  Forum: By Share Code

Verharven
Posted on: Oct 15 2019, 12:09 PM


Group: Member
Posts: 851

Short positions are in for Wednesday last week and there was a change of just a decrease of 0.03 percentage points (14k shares) to 5.8%. So any closing out (at likely a big loss) was offset by opening new positions. Rinse and repeat until the magic pudding runs out of pudding.
  Forum: By Share Code

Verharven
Posted on: Oct 15 2019, 10:37 AM


Group: Member
Posts: 851

Fourth day in a row of >100k gross shorts. We'll find out this afternoon if there was a net opening or closing of shorts on decision day last Wednesday.
  Forum: By Share Code

Verharven
Posted on: Oct 15 2019, 08:33 AM


Group: Member
Posts: 851

He agreed earlier this year to stay on as chair when already was ready to retire in order to see if through until FDA approval. The job is done and this will be his last AGM and then pass the baton on to his successor soon after. I wish him well. Sobering to read how close it was to curtains in the early 2000s as bankruptcy loomed. I would have lost maybe $50k at the time which would have been painful, but I would have moved on. Out of the ashes here we are today and I've just bought a new BMW on the weekend thanks to CUV with 'just enough left over' to buy a couple of houses.....
  Forum: By Share Code

Verharven
Posted on: Oct 15 2019, 04:40 AM


Group: Member
Posts: 851

I think they had a hand too in helping Eliud Kipchoge break the 2 hour marathon barrier on the weekend - he used to be white 😂
  Forum: By Share Code

Verharven
Posted on: Oct 14 2019, 02:53 PM


Group: Member
Posts: 851

But charting doesn't tell you if there was a legitimate reason for the gap in the first place - a binary event of FDA approval causing a major SP spike is a major rerating event of this company
  Forum: By Share Code

Verharven
Posted on: Oct 14 2019, 11:09 AM


Group: Member
Posts: 851

On balance, shorting is a zero-sum game as the selling will always be offset by the buying. You can argue that going long is also a zero-sum game, but with the big difference that timeframes for going long can be years (if not decades for many of us here!) whereas shorting is certainly a short-term game. So what happens between the two sides of the transaction of either short or long is a combination of fundamentals and some degree of irrationality/psychology (hype pushing up the SP and FUD pushing it down) and a dash of manipulation too. You'd only short then if you believe the SP overall was on the way down because of the belief it was overpriced and/or bad news was likely or you want to trigger a sell off, The shorters have FUed up all of these as the fundamentals have been franked by the FDA decision and I see little evidence of the shorting causing a panic pile-in of selling to create the SP direction the shorters need. I mean seriously, those of the many of us here that have been in for many years have seen the terrible times and are now sitting on multi-bagger profits - yeah right, as if any of us would be having sleepless nights if the SP were to drop 20%, 30 or even 40% from shorters. The fundamentals are going to steamroll them every time like it has with the FDA decision but they're yet to line up to take their medicine and close out.
  Forum: By Share Code

Verharven
Posted on: Oct 13 2019, 12:22 PM


Group: Member
Posts: 851

Yes, if an acquiring company got enough shares in a hostile bid, they could steer the board, but unless they get >90% of shares then they can't acquire the company. As it is now the board have a blocking stake in any takeover attempt and even if they were ousted, that blocking stake is still there.
  Forum: By Share Code

Verharven
Posted on: Oct 12 2019, 04:20 AM


Group: Member
Posts: 851

Regarding takeovers, no matter how hostile the bid, it has no chance of occurring unless the directors agree to it as collectively they own over 10% of the shares and in order to compulsorily acquire all shares in a company, a bidder must amass greater than 90% of shares from agreeable shareholders before they are able to mop up the rest of them compulsorily. I have no idea what price PW would take, but pretty safe bet it would be 3 digits.
  Forum: By Share Code

Verharven
Posted on: Oct 10 2019, 12:36 PM


Group: Member
Posts: 851

Whoa. As they say: "You only find out who is swimming naked when the tide goes out." And the CUV tide is strong so being naked means it's easier to be screwed.
  Forum: By Share Code

Verharven
Posted on: Oct 10 2019, 12:07 PM


Group: Member
Posts: 851

And there you have it, shorts back up 2.65 percentage points on Friday, Oct 4 to be back at 5.77% (2.8 M shares). Same thing for NEA so it's some accounting quirk in reconciling the open shorts for these shares that are being algo shorted based on TA rather than fundamentals. It's great news to be at ATHs with little change in the open short positions and likely not much change from yesterday based on the gross data. The squeeze is coming...
  Forum: By Share Code

Verharven
Posted on: Oct 10 2019, 10:32 AM


Group: Member
Posts: 851

Only 106k gross shorts yesterday
  Forum: By Share Code

Verharven
Posted on: Oct 10 2019, 04:55 AM


Group: Member
Posts: 851

Still waiting for it to appear on the approved list of drugs so we can sift through the entrails of all the juicy approval docs

https://www.accessdata.fda.gov/scripts/cder...sSearch.process
  Forum: By Share Code

Verharven
Posted on: Oct 10 2019, 02:31 AM


Group: Member
Posts: 851

I'm calling that short data showing a fall of 2.74 percentage points a data blip error as occurred the same for NEA (the other share the TA algo short traders have been playing with) on the same day and also for both shares on Aug 13. Please take note that the data is 4 trading days old and applies to October 3 so has no relevance to the trading that happened yesterday. That is why the data can't be correct as no way could 1.3 M shorts have closed out on Oct 3 which was a day where 366k shares traded on the market and the SP didn't do much. I'm expecting it to probably bounce back to ~6% tomorrow. Next Tuesday though we'll get the data for short positions as it applied to yesterday's trading and would certainly be expecting to see a decent fall, but the shorters still have some way to go to close out - God bless them all.
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 04:04 PM


Group: Member
Posts: 851

Division of Dermatology assessment team decision was unanimous. Will be the same team assessing the vitiligo indication.
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 03:56 PM


Group: Member
Posts: 851

I noted that as being his very last remark before going into Qs - appreciated PW
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 12:08 PM


Group: Member
Posts: 851

Looks like another data blip error or the like on the shorts as showed a 2.74 percentage point fall for October 3! NEA showed the same data blip.
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 09:04 AM


Group: Member
Posts: 851

Indicative open is at $40 - will be a massive day
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 08:48 AM


Group: Member
Posts: 851

And here's the news from CUV. I'll see you all on the teleconference!


Attached File(s)
Attached File  Announcements.pdf ( 151.07K ) Number of downloads: 85

 
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 07:40 AM


Group: Member
Posts: 851

$30.10 atm, but very little buy and sell volume
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 03:54 AM


Group: Member
Posts: 851

CLVLF up 26% to USD 23.25 which is AUD 34.54. How would it feel to be holding 2.9 M of open shorts right now?
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 03:40 AM


Group: Member
Posts: 851

Callback to our famous former Prime Minister Bob Hawke on when Australia won the America's Cup in 1983

https://www.youtube.com/watch?v=s8mdHO2_Zo8
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 03:30 AM


Group: Member
Posts: 851

Just to make it official, here's the news on the FDA website

https://www.fda.gov/news-events/press-annou...s-rare-disorder
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 03:20 AM


Group: Member
Posts: 851

Congratulations to the entire CUV team - we've had our criticism of many things you've done over the years, but getting this to FDA approval from the ashes of where it was in the mid 2000s is a true testament to the work and dedication of you all.
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 02:36 AM


Group: Member
Posts: 851

ASX rules are that THs can only be in place for a maximum of 2 trading days so they all read like this to give the company the full 2 days or until they make an announcement.
  Forum: By Share Code

Verharven
Posted on: Oct 9 2019, 02:09 AM


Group: Member
Posts: 851

It's 3 am here in Melbourne and just woke up and no way am getting back to sleep so here joining the 'Night's Watch'. I'm only a 10-minute drive from the head office at this time of the night - wonder if I should make the trip in to see if the lights are on 😂 Good luck to us all
  Forum: By Share Code

Verharven
Posted on: Oct 8 2019, 05:50 PM


Group: Member
Posts: 851

Thanks for that update as there was trading volume going through after the TH announcement came through so seems it's shut down now.
  Forum: By Share Code

Verharven
Posted on: Oct 8 2019, 05:17 PM


Group: Member
Posts: 851

So we didn't get the nice T-30 days SP run-up though we can thank the shorters for this. What is of interest from this graph is the SP action in the few days before a PDUFA decision. A nice spike up on average in the days prior to when a positive decision comes and a steep spike down on average in the days before bad news hits. The last three days have been very green so taking that as a good omen.
Attached image(s)
Attached Image

 
  Forum: By Share Code

Verharven
Posted on: Oct 8 2019, 05:06 PM


Group: Member
Posts: 851

Only the ASX - it's trading in Germany right this second. In this instance though news on the outcome will likely be released after the close of the US market so no other borse will get the jump on the news as ASX trading should be happening some time tomorrow once CUV get their announcement typed up.
  Forum: By Share Code

Verharven
Posted on: Oct 8 2019, 07:14 AM


Group: Member
Posts: 851

If you put a sell limit at $45 then that is the lowest price that a trade would go through at. If the shares came out of a TH where the SP was below $45 prior to it, then the order would be triggered if the opening single price auction was above $45 at the actual opening price. As for selling any shares if approval comes through, I'll see what the SP action is like but like many here, I believe it will be some months before the price starts to ramp up notwithstanding any single day price spike on approval day.
  Forum: By Share Code

Verharven
Posted on: Oct 7 2019, 12:29 PM


Group: Member
Posts: 851

Here's the list of the worth of the top 20 https://en.wikipedia.org/wiki/Forbes%27_lis...s#2018_rankings so if you wanted Newcastle United @ USD381M (AUD654) then based on PWs shares - say he has 4M (correct me if I'm wrong as can't be bothered looking it up) then would be a SP of AUD 141. He probably wants a Dutch team so SP well below that then.
  Forum: By Share Code

Verharven
Posted on: Oct 7 2019, 09:19 AM


Group: Member
Posts: 851

So if you knew a negative outcome was coming would you ink a new contract for more years of grind ahead? Or if you knew a positive outcome was coming, sign a new deal so you can build the company and SP further to get your football team in 3 years?
  Forum: By Share Code

Verharven
Posted on: Oct 7 2019, 08:04 AM


Group: Member
Posts: 851

Let's hope we'll be singing this on Wednesday

Hallelujah
  Forum: By Share Code

Verharven
Posted on: Oct 7 2019, 07:31 AM


Group: Member
Posts: 851

The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck

https://www.benzinga.com/general/biotech/19...-2-ipos-on-deck
  Forum: By Share Code

Verharven
Posted on: Oct 5 2019, 04:56 AM


Group: Member
Posts: 851

CUV hits the mainstream - now features in university chemistry assignments

https://www.chegg.com/homework-help/questio...pepud-q40576203
  Forum: By Share Code

Verharven
Posted on: Oct 2 2019, 09:46 AM


Group: Member
Posts: 851

FDA 'miscommunicated' the PDUFA date - should have been 8 October which aligns with a 3-month extension from the prior date of July 8. I guess if this error was just picked up at the 11th hour could make the assumption the decision will be coming through on the 8th. This time next week we will know.


Attached File(s)
Attached File  Announcements.pdf ( 131.25K ) Number of downloads: 156

 
  Forum: By Share Code

Verharven
Posted on: Oct 1 2019, 06:49 PM


Group: Member
Posts: 851

"Why are so many germans invested in Clinuvel Pharmaceuticals?"

Spoiler alert: Answer is Florian Homm

https://www.youtube.com/watch?v=wlj1L1HSrxU
  Forum: By Share Code

Verharven
Posted on: Sep 30 2019, 03:49 PM


Group: Member
Posts: 851

AGM announced for Wednesday 20 November, 10 am @ The Events Centre at Collins Square, Tower 2, Level 5, 727 Collins Street. Let's hope it's a party mood for all attending. It hopefully will be Stan's last AGM so am sure he'll go out with a bang with the jokes.


Attached File(s)
Attached File  Announcements.pdf ( 109.71K ) Number of downloads: 79

 
  Forum: By Share Code

Verharven
Posted on: Sep 30 2019, 08:17 AM


Group: Member
Posts: 851

If approval comes through, I was planning on selling a modest parcel of ~20k shares, but have now changed those plans and will hold through because....shorters - want to see them squeezed to an inch of their life to learn them a lesson good. I encourage you all to join in a selling strike if we get approval! 😂
  Forum: By Share Code

Verharven
Posted on: Sep 29 2019, 07:24 PM


Group: Member
Posts: 851

June 2003 was when i first bought into CUV (Epitan as it was back then) and picked up 5,000 shares @ $3.40 (consolidation adjusted). Since that time I've made 27 more purchases over the interceeding 16 years. It has been quite the journey as I find myself in possession of far more shares than I could have ever imagined all 'thanks' to the excruciating delays and long time frames that things have happened in which I hope to look back on as a blessing in a bit under a week. This board has maintained my sanity and served as one of the most valuable resources (and support groups) I've known. Good to luck to everyone as we wait to get the news we wish for hopefully in the early hours of Saturday morning Australian time.
  Forum: By Share Code

Verharven
Posted on: Sep 27 2019, 04:03 PM


Group: Member
Posts: 851

The 1.82% is the sum total of the % Capital Shorted column which is not correct as the data is non-aggregate and the timeframe is arbitrary - you could do it back for the last year or 5 years or whatever time you like and get a huge number
  Forum: By Share Code

Verharven
Posted on: Sep 27 2019, 03:48 PM


Group: Member
Posts: 851

There is no mismatch - the data that matters is the open short positions which trail by 4 days. It looks like you've just added up the gross short column and the % capital shorted over the arbitrary time frame back to 30 August which is not how it is done as you don't just add all this data together cumulatively. Gross shorts give a rough guide to the day's trading as there could be multiple open and closing of positions.
  Forum: By Share Code

Verharven
Posted on: Sep 25 2019, 01:13 PM


Group: Member
Posts: 851

And the shorts shoot up to 6.15% (3.01 M shares) as of Thursday of last week. This was the day where there were 160k shares traded on the opening bell and 476k for the day.
  Forum: By Share Code

Verharven
Posted on: Sep 23 2019, 02:46 PM


Group: Member
Posts: 851

When you're short, the maximum profit you can make is your initial investment from selling the shares (minus the shorting loan fee) if the company were to go belly up (so don't need to repurchase the shares) while your maximum losses are unlimited. It is not a long-term strategy.
  Forum: By Share Code

Verharven
Posted on: Sep 23 2019, 02:15 PM


Group: Member
Posts: 851

Yes and as I write this, CUV is down 3.68% and NEA down 3.56% on a slightly green day for the market. It's TA shorting all the way - they probably have no idea what PDUFA even stands for.
  Forum: By Share Code

Verharven
Posted on: Sep 23 2019, 01:17 PM


Group: Member
Posts: 851

Look no further than the shorters to explain all this as the open shorts hit a new all-time high of 5.94% (2.906M shares) as of Tuesday of last week.
  Forum: By Share Code

Verharven
Posted on: Sep 21 2019, 05:26 AM


Group: Member
Posts: 851

If the shorter is betting on a CRL then good luck to them as nothing is 100% certain, but they're certainly not doing it based on any privileged information as the shorting has been going on for 2 months yet we had a director buying only a few weeks ago. Of course, a director could not buy if they were in receipt of privileged information on a likely approval and equally could not sell if they knew a CRL was on the cards, but they could choose 'not to buy' if they had information of a likely CRL
  Forum: By Share Code

Verharven
Posted on: Sep 21 2019, 05:02 AM


Group: Member
Posts: 851

Yes, that's my understanding as Vyleesi had a PDUFA date that fell on a Sunday, but the outcome was released to the market COB on the Friday before.
  Forum: By Share Code

Verharven
Posted on: Sep 19 2019, 10:06 AM


Group: Member
Posts: 851

168k shares traded on the opening bell 😮
  Forum: By Share Code

Verharven
Posted on: Sep 18 2019, 04:50 PM


Group: Member
Posts: 851

One word: arbitrage. Companies trading on multiple exchanges will always be close in price (so long as sufficient trading volume) as any drift from this opens up an arbitrage opportunity which markets players will seize on for a quick profit which restores the market balance.
  Forum: By Share Code

Verharven
Posted on: Sep 18 2019, 09:44 AM


Group: Member
Posts: 851

Hoping that the worm has finally turned


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Sep 13 2019, 03:41 PM


Group: Member
Posts: 851

It's shorting driven by technical analysis mostly in my eyes. TA though isn't going to tell you if the FDA decision is going to be yay or nay as the shorting has been happening since early July so there is really little chance of somehow 'inside' knowledge of a pre-ordained negative decision. I think the shorters have gay abandon for the PDUFA date which consensus here seems to be much better odds than 50:50 for approval so is playing with fire and I for one will rejoice in the pain inflicted on the shorters if they are still open if a positive decision comes in.
  Forum: By Share Code

Verharven
Posted on: Sep 12 2019, 04:34 PM


Group: Member
Posts: 851

Shorters only 'wreck' a company if they cause a pile on in selling from actual holders of the stock and I don't see much evidence of that happening. Every short MUST be closed out by buying back in again so there is a lot of buying demand now in the wings so everything that happens in between is mostly about the fundamentals.
  Forum: By Share Code

Verharven
Posted on: Sep 10 2019, 11:47 AM


Group: Member
Posts: 851

Here are the 12 month short and SP graphs for CUV and NEA - try to spot the difference.


Attached thumbnail(s)
Attached Image

Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Sep 4 2019, 08:18 AM


Group: Member
Posts: 851

Where has all the buy and sell volume gone???


Attached thumbnail(s)
Attached Image



 
  Forum: By Share Code

Verharven
Posted on: Aug 28 2019, 02:52 PM


Group: Member
Posts: 851

First daily fall in net shorts since July 12 (not counting the clearly data blip error from Aug 13 of a near 2.5 percentage point fall). The rise in shorts over this time has been far steeper than the decline in the share price.
  Forum: By Share Code

Verharven
Posted on: Aug 28 2019, 01:25 PM


Group: Member
Posts: 851

So they had to reissue the financial report because they forgot to add the independent auditor's declaration. They're also yet to pick up that they stuffed up something as simple as giving a record and ex date for the dividend. Record date is given as Thursday 5 Sep with the ex date of 17 Sep! To start with, ex dates are one trading day BEFORE a record date so no idea how on earth they came up with this. Two very embarrassing amateur errors.
  Forum: By Share Code

Verharven
Posted on: Aug 23 2019, 11:58 AM


Group: Member
Posts: 851

Last year, preliminary financial results and dividend announced Wednesday, August 29. The year before it was Wednesday, August 30 so expecting this mid next week. I'm going for a $0.05 divvy
  Forum: By Share Code

Verharven
Posted on: Aug 20 2019, 03:08 PM


Group: Member
Posts: 851

As for shorts...next minute, we're back up at 5.46%!! And noted NEA also jumped as well to be just above where it was two trading days before so it's technical games being played.
  Forum: By Share Code

Verharven
Posted on: Aug 19 2019, 01:39 PM


Group: Member
Posts: 851

Showing how meaningless really daily gross shorts data is, open short positions just fell from 5.22% to 2.76% as of August 13 when gross shorts for that day were 78k.
  Forum: By Share Code

Verharven
Posted on: Aug 14 2019, 01:10 PM


Group: Member
Posts: 851

Yes, shorts just ticked over the 5% mark today (as of August 8 - 5.01%) and there hasn't been a day decline in short positions since July 12 when they were at 2%. The SP weathered the first 2-3 weeks of it, but not so the last 1-2 weeks.
  Forum: By Share Code

Verharven
Posted on: Aug 14 2019, 08:59 AM


Group: Member
Posts: 851

And we're set for another day with a spike in the SP on open (currently predicted at $28.49 with excess buy volume) likely only to be ground down over the course of the day by shorters. This game of musical chairs can only be played for so long and the end of the song is approaching.
  Forum: By Share Code

Verharven
Posted on: Aug 13 2019, 05:23 AM


Group: Member
Posts: 851

An update from MinusSinus

https://seekingalpha.com/article/4284940-ta...ation?dr=1#alt2


Clinuvel Has More Aces Up Their Sleeves - A Monte Carlo Valuation

Summary

Clinuvel Pharmaceuticals is waiting to get an FDA response for the first treatment of EPP patients in the US by Oct. 2019.

The stock has risen significantly from the anemic trading during the last decade, but is the stock price still covered by the underlying business value?

A Monte Carlo analysis over the three applications of EPP, VP, and Vitiligo shows a median fair value of 32.5 USD/share, with the 10-90% confidence interval being 20-62 USD/share.
  Forum: By Share Code

Verharven
Posted on: Aug 13 2019, 05:19 AM


Group: Member
Posts: 851

The Homm effect? Germany went a little crazy last night with high volume and close of EUR 17.30 (AUD 28.73) even peaking at EUR 17.79 (AUD 29.54)
  Forum: By Share Code

Verharven
Posted on: Aug 8 2019, 03:18 PM


Group: Member
Posts: 851

Just adding to the recent posts - I topped up on Tuesday and so too have a few family members who have been in it for some time. Think it's a great price now to buy-in for where we are at - global markets will do what global markets do.
  Forum: By Share Code

Verharven
Posted on: Aug 5 2019, 03:57 PM


Group: Member
Posts: 851

If it makes things any better, the biotech peers to CUV of PME and NAN are down a similar amount today
  Forum: By Share Code

Verharven
Posted on: Aug 5 2019, 01:41 PM


Group: Member
Posts: 851

Something I've posted before is the graph below taken from the thesis here It's 35-45 days pre-decision date that the SP ramp-up begins so hopefully CUV will follow this trend. If you were a shorter you should be aware of this timeline to be looking at closing out by then unless you were uber-confident of a negative decision, but if so you'd be nuts to short now - just do it before the decision when the SP should be at its potential highest and then reap the reward of the SP crash soon after.


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Jul 31 2019, 09:22 AM


Group: Member
Posts: 851

Quarterly out: $13.0 M in receipts and $54M in the bank smile.gif


Attached File(s)
Attached File  Announcements.pdf ( 450.98K ) Number of downloads: 164

 
  Forum: By Share Code

Verharven
Posted on: Jul 12 2019, 12:20 PM


Group: Member
Posts: 851

I've posted before that CUV and NEA have been tracking each other quite closely the last few months (apart from when NEA got the ASX200 inclusion bump earlier for its out-of-cycle addition) and today NEA is down over 7% so seems technical trading with the new ASX200 entrants rather than any fundamentals.
  Forum: By Share Code

Verharven
Posted on: Jul 10 2019, 01:15 PM


Group: Member
Posts: 851

ASX200 stocks sorted by 1-year price change. Things aren't too bad are they.
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Jun 29 2019, 09:24 AM


Group: Member
Posts: 851

No, Vyleesi is given subcutaneously just like botox which can also be given intramuscularly with similar efficacy. Scenesse is given as an implant subcutaneously though is a bit more of an involved procedure than a simple injection
  Forum: By Share Code

Verharven
Posted on: Jun 26 2019, 02:31 PM


Group: Member
Posts: 851

More like snorting it tongue.gif
  Forum: By Share Code

Verharven
Posted on: Jun 26 2019, 06:23 AM


Group: Member
Posts: 851

Just something I've noticed recently and the 6-month graph below confirms it, is that CUV and Nearmap have had a very similar story over the last 12 months. They're both the best 1-year performing stocks on the ASX200 - up over 200% and apart from the SP bump that NEA got earlier from being added to the ASX200 on April 15 from MYO being removed, they track closely. Note the downturn they've both experienced in recent days so could indicate TA traders are having a say in both.
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Jun 25 2019, 05:46 AM


Group: Member
Posts: 851

I think he was more coming from the reality that an injection mode of delivery will be much less popular/saleable than a pill so this will affect take up. I agree with his views on efficacy now I've looked more closely at the trial results plus there is the established competitor on the market too which is in pill form.

Agree with other comments that we're probably in for a period of SP flat line/dipping for a while as we bob along without many big price drivers and the SP seems reasonably priced now based on future EU earnings and a bit of FDA speculation. But it is great to know that there has been all this short action absorbed into the SP so that will be a nice buffer if the SP drops further and the shorts close out.
  Forum: By Share Code

Verharven
Posted on: Jun 24 2019, 01:02 PM


Group: Member
Posts: 851

Just looked at Shortman: there were 615k gross shorts on Friday so that explains a lot of the extra volume that went through. Shorters gonna short - worked out so well for them over the last few months tongue.gif
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 06:48 PM


Group: Member
Posts: 851

Top marks to the SPDR ASX200 ETF fund - already updated their holdings. They picked up 96,817 shares. Where the hell did all the other shares go as the SPDR fund is one of the big ETFs???

https://www.spdrs.com.au/etf/fund/spdr-sp-a...0-fund-STW.html
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 10:46 AM


Group: Member
Posts: 851

When Viagra was launched in the US market, half a million scripts were written in the first month. When Addyi was launched in October 2015, it was only prescribed to a little over 200 patients in the first month. By February 2016, the total number of scripts written was less than 4,000. Can't find current data, but clearly, a blockbuster this drug ain't nor will Vyleesi be either so PTN investors seem to have got a little bit 'over excited' (see what I did there) by approval or have an eye to future indications.
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 10:14 AM


Group: Member
Posts: 851

Hmm, perhaps, but there is already a drug on the market to treat pre-menopausal HSDD - Addyi (flibanserin). Addyi increases the number of satisfying sexual events per month by about one half over placebo. Compare that to Vyleesi which did not change the number of satisfying sexual events compared to placebo. Addyi also seems to have less side-effects and contraindications for its use.
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 08:55 AM


Group: Member
Posts: 851

Makes CUV's marketing a walk in the park. An extremely well-defined, small and accessible population just about all of who will know about the only effective treatment so far for EPP. PTN are going to have to invest big in marketing to get the word out just to tip enough doctors over that they'll prescribe it.
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 08:27 AM


Group: Member
Posts: 851

These are far from impressive results - a very small increase in self-reported sexual desire in ONLY 25% of women compared to 17% that also saw a benefit in the placebo group?! And look at the decrease in distress scores - hardly any difference in the drug vs placebo in % of women that saw a drop?! This is great though if this is the benchmark of efficacy that the FDA uses. They only would have got these as significant differences because of the large sample size so while statistically significant, the overall benefit across a population is small.

"The effectiveness and safety of Vyleesi were studied in two 24-week, randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women with acquired, generalized HSDD. Most patients used Vyleesi two or three times per month and no more than once a week. In these trials, about 25% of patients treated with Vyleesi had an increase of 1.2 or more in their sexual desire score (scored on a range of 1.2 to 6.0, with higher scores indicating greater sexual desire) compared to about 17% of those who took placebo. Additionally, about 35% of the patients treated with Vyleesi had a decrease of one or more in their distress score "(scored on a range of zero to four, with higher scores indicating greater distress from low sexual desire) compared to about 31% of those who took placebo."
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 07:49 AM


Group: Member
Posts: 851

I wouldn't describe it a 'useless' drug. Hypoactive sexual desire in women can cause personal distress and relationship problems so can affect quality of life. Kinda like the long-term psychological and quality of life problems that arise from not being able to go out and enjoy the world during daylight hours...
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 06:15 AM


Group: Member
Posts: 851

So feel for the UK EPP sufferers for how this has dragged on - all starting with NICE 'misclassifying' the approval track to start wtih and not giving it HST status off the bat - so much time wasted from that. I can't fault CUV though for how aggressively they've fought this every step of the way. At least a negative decision is already priced into the SP.
  Forum: By Share Code

Verharven
Posted on: Jun 22 2019, 06:03 AM


Group: Member
Posts: 851

So with the ASX200 speculation behind us and with a PDUFA date still over 3 months away, what's there to fill in the void?

1. The next quarterly end of Jully (I am projecting ~$15M in receipts)
2. Getting overdue for news on the NICE re-assessment decision
3. Dividend. Sure, it was only $0.02 ps (~$1M) last year, but they've set the precedent and cash has only grown in the bank since then. Maybe they'll go crazy and double it to $0.04

Anything else? I can't see NASDAQ happening until after a FDA decision (that is positive) as they won't be running new trials to pursue new indications there unless they know the drug is looked upon favourably so hard to sell the story to the US market without that.
  Forum: By Share Code

Verharven
Posted on: Jun 21 2019, 04:11 PM


Group: Member
Posts: 851

Close @ $38.55 with a volume of 1.86M so that was 1.4M after the close.
  Forum: By Share Code

Verharven
Posted on: Jun 21 2019, 04:04 PM


Group: Member
Posts: 851

1.7M on the buy side, 1.7M on the sell side. Indicative price of $38.79
  Forum: By Share Code

Verharven
Posted on: Jun 21 2019, 04:01 PM


Group: Member
Posts: 851

And here come the ETFs...



Attached thumbnail(s)
Attached Image



 
  Forum: By Share Code

Verharven
Posted on: Jun 21 2019, 03:59 PM


Group: Member
Posts: 851

1 minute to close and the buy volume just doubled to 272k
  Forum: By Share Code

Verharven
Posted on: Jun 21 2019, 02:23 PM


Group: Member
Posts: 851

Bit of a mid-arvo frenzy happening - real on market buying, no more bots. What will 4pm bring...


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Jun 21 2019, 11:51 AM


Group: Member
Posts: 851

Clinuvel moves digs to Level 11, 535 Bourke St (only 650 metres by foot from their prior Queen St offices). Hopefully, because they needed more space... Nicer part of the world though.

If you look here on Google Stree View, you can see PW's moto out the front decked in CUV colours,

https://www.google.com/maps/place/535+Bourk...3;4d144.9580248


Attached File(s)
Attached File  Announcements.pdf ( 109.27K ) Number of downloads: 70

 
  Forum: By Share Code

Verharven
Posted on: Jun 20 2019, 09:32 AM


Group: Member
Posts: 851

Because the clinical trials need to 'prove' it helps lower the risk of skin cancer would take years, if not decades to do. And as for a 'sunscreen' replacement, that isn't going to fly at this stage for something that requires a surgical intervention to administer. This is all future gazing when topicals make it into development.
  Forum: By Share Code

Verharven
Posted on: Jun 20 2019, 08:01 AM


Group: Member
Posts: 851

Astaxanthin does have an effect on reducing UV damage so that a person taking it can tolerate a higher 'dose' of sun before a sunburn occurs, but certainly not in the same league as sunscreen. Following is one of the first clinical trials in this area, and you can find anecdotes online of fair skin people taking it reporting that they can be out in the sun longer without getting burnt. Pretty confident it isn't much of a benefit for EPP else the community would have been on to it years ago seeing as a bottle costs a few dollars and is OTC. Fun fact: flamingos are born white, but turn pink as they develop from eating algae that make astaxanthin. Another fun fact: salmon is naturally white, but becomes pink/red from all the krill it eats which, as you may guess, is full of astaxanthin.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073124/

The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People—A Randomized, Double-Blind, Placebo-Controlled Trial

Skin is a major safeguard tissue in humans. Because biological barrier function is deteriorated by several kinds of stresses including exposure to ultra-violet (UV) rays, the protection and treatment of skin conditions by dietary supplements are important. We therefore evaluated the effects of dietary supplementation with an algal food-derived antioxidant, astaxanthin, on UV-induced skin deterioration. Twenty-three healthy Japanese participants were recruited to a 10-week double-blind placebo-controlled study. They were assigned to the astaxanthin group supplemented with a capsule containing 4 mg of astaxanthin or the placebo group. To assess the protective role of astaxanthin for UV-induced skin deterioration, we determined the minimal erythema dose (MED) and analyzed UV-induced changes of moisture and transepidermal water loss (TEWL) at baseline and after 9 weeks of supplementation. Subjective skin conditions were assessed by the visual analog scale. The astaxanthin group showed increased MED compared with placebo. In addition, the astaxanthin group had a reduced loss of skin moisture in the irradiated area compared with placebo. Subjective skin conditions for “improvement of rough skin” and “texture” in non-irradiated areas were significantly improved by astaxanthin. Astaxanthin seems protective against UV-induced skin deterioration and helps maintain healthy skin in healthy people.
  Forum: By Share Code

Verharven
Posted on: Jun 19 2019, 02:53 PM


Group: Member
Posts: 851

Spot on. The biggest SP killer I've seen in recent times is CUV's newsletters - if you haven't got something clear and unambiguous to say, then don't say anything at all. I pray that Stan and PW STFU until October 6.
  Forum: By Share Code

Verharven
Posted on: Jun 19 2019, 02:13 PM


Group: Member
Posts: 851

It's good volume, but my screen shows me it is 'only' double the average last 3-month volume so has been building for some time.
  Forum: By Share Code

Verharven
Posted on: Jun 18 2019, 02:12 PM


Group: Member
Posts: 851

So the index ETFs stay true to their mission and buy and sell at the rebalance and play it by the numbers, so unless a large holder/insto steps in as an opportunity to off-load, where are these needed shares going to come from on Friday? Hint: not mine. Could be the greenest of green days on Friday....
  Forum: By Share Code

Verharven
Posted on: Jun 18 2019, 09:38 AM


Group: Member
Posts: 851

Here you go. I like the look of the sell depth


Attached image(s)
Attached Image

 
  Forum: By Share Code

Verharven
Posted on: Jun 18 2019, 08:28 AM


Group: Member
Posts: 851

Gang, James no longer thinks CUV is expensive!

https://www.fool.com.au/2019/06/18/the-clin...6-in-12-months/

The Clinuvel Pharmaceuticals share price is up 236% in 12 months

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price was an impressive performer on Monday.

The biopharmaceutical company’s shares raced to an all-time high of $36.98 before finishing the day 7% higher at $36.49.

When Clinuvel’s shares hit the $36.98 mark, it meant they had gained a staggering 236% since this time last year.

Why is the Clinuvel Pharmaceuticals share price on fire?
This latest gain appears to have been driven by the company’s recent inclusion in the benchmark S&P/ASX 200 index at the June quarterly rebalance.

It was added to the index after meeting the ranking requirements for the S&P/ASX 200 based on its float-adjusted market capitalisation and median liquidity over the past six months.

But the key driver of its share price gain over the last 12 months has been the success of its SCENESSE product.

SCENESSE has been developed as a first-line pharmaceutical product aimed at treating patients with the rare genetic disorder erythropoietic protoporphyria (EPP).

A few years ago management made the strategic decision to self-distribute SCENESSE. Together with its decision to oversee and manage the supply chain and build a network of accredited centres of porphyria expertise, this has underpinned the company’s impressive sales growth.

During the March quarter the company reported cash receipts of $5.9 million, which was an increase of 126% on the previous quarter and 70% on the prior corresponding period.

And this does not include sales in the United States as SCENESSE is not yet available in this key market. But if all goes to plan, the company could be generating sales in the United States in the near future.

The US FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of October 6 to provide it with time for a full review of the submission of the SCENESSE scientific dossier. If the regulatory body gives SCENESSE the tick of approval, it could lead to a solid increase in sales.

Time will tell whether it is the next CSL Limited (ASX: CSL), but Clinuvel certainly is worth watching closely.
  Forum: By Share Code

Verharven
Posted on: Jun 16 2019, 11:58 AM


Group: Member
Posts: 851

That $0.50 was really just about short-term for knowns based on EU role out and not even considering potential other markets post FDA so certainly on the metrics, CUV is not an 'expensive' stock and perhaps could even be considered a little undervalued, but I'll take $34 any day of the week from the base we've come from :-)
  Forum: By Share Code

Verharven
Posted on: Jun 16 2019, 10:55 AM


Group: Member
Posts: 851

Good question. From MorningStar data from my trading platform, for 2020 forward P/E you are looking at:

PME: 139
NAN: 107

There is no data for CUV for 2019 or 2020, so really comes down to what EPS you want to plug in. Current P/E of 127 is based on an EPS of $0.267 though this a little out of date it seems as I've just realised, as should be an EPS of 0.332 to give a P/E of 102 according to data on the ASX and another site and using that data, gives a current P/E for NAN of 138 and for PME 146. So based on current P/E, CUV is well below its peers.

Not unreasonable to see an EPS at perhaps $0.50 in the near future so you have a forward P/E of 68 so makes CUV look even better compared to its peers on their forward P/Es for potential price growth.
  Forum: By Share Code

Verharven
Posted on: Jun 16 2019, 08:32 AM


Group: Member
Posts: 851

Just looked at a couple of biotech peers to CUV as far as MC range and also are making money.

PME has a MC of $2.4B and a P/E of 152
NAN has a MC of $1.5B and a P/E of 116

Compare that to CUV with its MC of $1.7B and P/E of 127

If you look at the most mature of biotechs going around such as CSL, RMD and COH, they have P/Es in the rage of 35-45 so for any long-term conservative price guesstimation, this would be the appropriate P/E to use.

So the summary is that the P/E for CUV is quite reasonable atm especially considering the profit growth still happening from Europe as EPS will bump up a lot this year and the rest of the price comes from anticipating a positive FDA decision.
  Forum: By Share Code

Verharven
Posted on: Jun 15 2019, 08:06 AM


Group: Member
Posts: 851

One more ASX200 ETF - it's German based and pretty small, but every bit helps

Xtrackers S&P ASX 200 UCITS ETF

https://www.bloomberg.com/quote/XAUS:GR
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 04:12 PM


Group: Member
Posts: 851

ASX200 means a bump from ETF index fund buying 'locking away' the shares. Also opens up CUV to funds that have rules that only allow them to buy ASX200 companies and then the signal that is sent to the wider community that this is a serious company now. CUV now sits in the top 150 companies on the ASX.
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 01:33 PM


Group: Member
Posts: 851

The one to watch is SPDR S&P/ASX 200 Fund as has a MC similar to the Vanguard ASX300 fund which has 371k CUV shares. The iShares ETF has a MC about one-third of the others. The BetaShares Australian 200 ETF is the minow of the group and has 12k shares.
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 01:11 PM


Group: Member
Posts: 851

iShares Core S&P/ASX 200 ETF

SPDR S&P/ASX 200 Fund

CUV is already in the portfolio of the BetaShares A200 as uses a slightly different methodology index to the ASX200

Then there is BetaShares FTSE RAFI Australia 200 ETF which some outlets say tracks the ASX200, but is based on a top 200 index based on economic footprint, not MC. CUV is not currently one of their holdings.
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 10:12 AM


Group: Member
Posts: 851

It's looking just fine


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 09:53 AM


Group: Member
Posts: 851

So right now, CUV sits at position 151 on the ASX200 index and second best 1-year performer only just behind Nearmap. How's the calcs looking for the ASX100 waz? lmaosmiley.gif
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 08:01 AM


Group: Member
Posts: 851

ASX200 rebalance announcement out and it's CUV, SSM and ASB in and SWM, SYR and NVT out.

Props to waz


Attached File(s)
Attached File  943758_2019.06.14_quarta_200.pdf ( 184.43K ) Number of downloads: 193

 
  Forum: By Share Code

Verharven
Posted on: Jun 14 2019, 07:45 AM


Group: Member
Posts: 851

It's 2018 :-)
  Forum: By Share Code

Verharven
Posted on: Jun 11 2019, 10:17 AM


Group: Member
Posts: 851

Book looking very good

Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: Jun 10 2019, 09:21 AM


Group: Member
Posts: 851

Heads up for our overseas friends, it's the Queen's Birthday public holiday here in Oz so no ASX trading. Long may her majesty reign and rule over her colony.
  Forum: By Share Code

Verharven
Posted on: Jun 8 2019, 06:30 AM


Group: Member
Posts: 851

Nice to see the US leading the way overnight up 2.25% and closing at USD 22.75 (AUD 32.49) and hitting an intra-day high of USD 23.07 (32.95). Maybe the US roadshow is attracting a bit more interest?
  Forum: By Share Code

Verharven
Posted on: Jun 6 2019, 06:52 PM


Group: Member
Posts: 851

Someone wrote a while back that they can't be considered as too much of their stock is tightly held by directors etc that's why MC calculation for the index inclusion is based on the free-float sahres, not the total number of shares
  Forum: By Share Code

Verharven
Posted on: Jun 6 2019, 04:00 PM


Group: Member
Posts: 851

Friday week the 14th
  Forum: By Share Code

Verharven
Posted on: Jun 4 2019, 03:23 PM


Group: Member
Posts: 851

From the FDA: Please Accelerate Approval of the Life Changing Afamelanotide for EPP Facebook group https://www.facebook.com/pg/AccelerateAppro...lanotide/posts/

"Not happy about this. The FDA has pushed their decision date to October. Everyone needs to contact their state representatives to help us and apply pressure. This is just a delay tactic by the FDA!"
  Forum: By Share Code

Verharven
Posted on: Jun 4 2019, 08:26 AM


Group: Member
Posts: 851

Seriously quality post you put up - props for doing all that research - feeling a bit better about things today!
  Forum: By Share Code

Verharven
Posted on: Jun 3 2019, 02:59 PM


Group: Member
Posts: 851

Was expecting a SP drop below $30 today so held up well and there are valid reasons this time for such a large fall though in the scheme of the rise over the last few weeks, the SP looks great! I'm very bullish on ASX200 inclusion so that should give a good buying support base plus those mass of shorts will have to come back eventually and probably a few more added today.
  Forum: By Share Code

Verharven
Posted on: Jun 3 2019, 01:16 PM


Group: Member
Posts: 851

So Shortman has now updated to include all that huge volume in the after close trade from Tuesday of last week and open shorts jumped by 401k to 1.03M open positions.
  Forum: By Share Code

Verharven
Posted on: Jun 3 2019, 09:10 AM


Group: Member
Posts: 851

PDUFA date now extended to October 6
Attached File(s)
Attached File  Announcements.pdf ( 162.4K ) Number of downloads: 337

 
  Forum: By Share Code

Verharven
Posted on: Jun 1 2019, 07:21 PM


Group: Member
Posts: 851

I'm Iggy and so is my wife!
  Forum: By Share Code

Verharven
Posted on: Jun 1 2019, 05:34 PM


Group: Member
Posts: 851

Yes, what this indicates is what I have had a gut feel about in that negative and positive Phase III trial results can 'leak' out into the market, while a FDA decision outcome is a pretty tight ship so no noticeable difference in the price run-up for those that end up getting a positive vs negative decision. Though the data from this study was a fairly small sample size and was just oncology drugs.
  Forum: By Share Code

Verharven
Posted on: May 30 2019, 05:29 PM


Group: Member
Posts: 851

Yes, that is the other strong possibility so just as good an outcome as the sell has already occured so will support the SP post outcome whatever the decision when closing out. And thanks for raising the CGT reason as I was trying to understand why you would go to the hassle and extra expense to short when you can just sell some of your own holding now for pretty much the same outcome.
  Forum: By Share Code

Verharven
Posted on: May 30 2019, 02:46 PM


Group: Member
Posts: 851

More unwinding of short positions as I was expecting with total open positions now down to 547k as of last Friday so negatively correlating with the SP rise into the second part of last week as shorters took their medicine and headed for the exit. Probably another fall tomorrow in open shorts to take into account Monday's further SP rise and then on this coming Monday afternoon, will see where it bounces to take into account all the after close gross short action from Tuesday. Seriously, if you're shorting now this late in the day with the lead into a FDA decision run up and ASX200 inclusion price drivers, then you're betting the house on a negative FDA decision rather than CUV 'looks overbought'.
  Forum: By Share Code

Verharven
Posted on: May 28 2019, 08:39 PM


Group: Member
Posts: 851

From poster andyat over at Hotcopper

"CUV was added the MSCI Aus small cap index at close today. Not too many of the big boys are benchmarked to that, only one" I know of is Vanguards Small Cap ETF. At $250M, for each % in the benchmark they'll need close to 100k shares. If there are one or two other players using the same BM then that would explain the volume today."
  Forum: By Share Code

Verharven
Posted on: May 28 2019, 04:19 PM


Group: Member
Posts: 851

Only ever traded over 1M shares in a day twice before. Once was 6.1M in 2008 which was a fund getting out in one transfer. The other was in 2003 which was just over 1M, but of course, that was pre 10:1 consolidation days so really is 100k. As for liquidity, sadly won't do a lot as it is based on median liquidity over 6 months so would be 'better' to have say 10 days of 100k rather than all in one go. Who cares though, we'll be in the ASX200 sooner rather than later.
  Forum: By Share Code

Verharven
Posted on: May 28 2019, 04:11 PM


Group: Member
Posts: 851

Close at $35.16 with 833k shares going through at the close out.
  Forum: By Share Code

Verharven
Posted on: May 28 2019, 04:02 PM


Group: Member
Posts: 851

Just hit 4pm and went from about 115k on the buy side and 30k on the sell side to instantly 595k on the buy side and 550k on the sell side.

Edit: 1M now on the buy side and 638k on the sell with an indicative price of $36 - see where this goes at the 4:10pm close out...
  Forum: By Share Code

Verharven
Posted on: May 28 2019, 11:16 AM


Group: Member
Posts: 851

Sunscreen??? Come on waz, this is CUV - it's a complimentary implant for all SHers so we can all sport the PW glow 😂
  Forum: By Share Code

Verharven
Posted on: May 28 2019, 10:08 AM


Group: Member
Posts: 851

It's a feeding frenzy and shorters are the main course. Still over 700k of them open as of last Tuesday.


Attached thumbnail(s)
Attached Image



 
  Forum: By Share Code

Verharven
Posted on: May 25 2019, 05:30 AM


Group: Member
Posts: 851

You can probably take all price mentions here to be AUD considering this is an Australian-based discussion board discussing an Australian-based company and where the German and US bourses follow the ASX price leads. Agree though, the falling Aussie dollar has not been kind to our overseas investor friends!
  Forum: By Share Code

Verharven
Posted on: May 24 2019, 08:05 PM


Group: Member
Posts: 851

Hey gang, James is back and guess what he's saying about CUV? His last sentence implies though that he thought they weren't overvalued in the past (like when he started calling them expensive when they were $24 in mid Feb) 😂

https://www.fool.com.au/2019/05/24/is-it-to...ing-asx-shares/


Is it too late to buy Telstra and these high-flying ASX shares?


The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price reached an all-time high of $32.22 on Thursday. The biopharmaceutical company’s shares have rallied significantly higher over the last 12 months thanks to the success of its SCENESSE product. SCENESSE is a first-line pharmaceutical product aimed at treating patients with the rare genetic disorder erythropoietic protoporphyria (EPP). In the March quarter the company reported cash receipts of $5.9 million, up 126% on the previous quarter and 70% on the prior corresponding period. This strong growth could be given a big boost in the near term if the U.S. FDA approves it for sale in the United States at its upcoming Priority Review. Whilst I think CLINUVEL is an exciting company, I feel its valuation is a little stretched now.
  Forum: By Share Code

Verharven
Posted on: May 24 2019, 12:58 PM


Group: Member
Posts: 851

$49 approved and $22 CRL
  Forum: By Share Code

Verharven
Posted on: May 24 2019, 10:14 AM


Group: Member
Posts: 851

Mark Knopfler's pickless style is speaking to me and saying Money for Nothing atm
  Forum: By Share Code

Verharven
Posted on: May 24 2019, 10:05 AM


Group: Member
Posts: 851

Here you go. $32.86 open
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: May 23 2019, 02:17 PM


Group: Member
Posts: 851

Not when there is lots of buyer demand (impending FDA decision and ASX200 inclusion being key), some of which could be previous shorts closing out to stop the bleeding of losses as we keep hitting ATHs.
  Forum: By Share Code

Verharven
Posted on: May 17 2019, 03:39 PM


Group: Member
Posts: 851

James, James, James - a not-so-subtle backhander to say that CUV is still too expensive which he started on about when they were under $24 with the only analysis he has ever provided to support this view is how much % they've risen. The Fool.


https://www.fool.com.au/2019/05/17/insiders...ese-asx-shares/

Insiders have been buying Macquarie and these ASX shares

Clinuvel Pharmaceuticals Limited (ASX: CUV)

A change of director’s interest notice reveals that non-executive director, Dr Karen Agersborg, has bought a number of this biopharmaceutical company’s American depositary receipts (ADRs) this month. According to the notice, Dr Agersborg picked up 1,200 of the company’s ADRs for an average of US$16.7804 per ADR. This equates to a total consideration of just over US$20,000 and brings her holding up to a total of 2,900 ordinary shares and 1,200 ADRs. Clinuvel’s shares have rallied 74% higher since the start of the year, but this director appears to still see value in them.
  Forum: By Share Code

Verharven
Posted on: May 17 2019, 01:17 PM


Group: Member
Posts: 851

I see that FDA link pop up quite a bit when I do time-restricted CUV searches so have learnt to not read too much into it now
  Forum: By Share Code

Verharven
Posted on: May 17 2019, 10:07 AM


Group: Member
Posts: 851

For those on 20-minute delay, spoiler alert


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: May 17 2019, 05:48 AM


Group: Member
Posts: 851

Big volume in CLVLY overnight of 119k shares which in the history of its trading, has only been surpassed 5 times and all of those occasions were in Oct/Nov 2014 at EMA approval time. But if you factor in SP, then by value it was the biggest trading day in its history by almost double the previous highest mark. Both German and US prices point to AUD 30.50.
  Forum: By Share Code

Verharven
Posted on: May 16 2019, 05:51 PM


Group: Member
Posts: 851

Agree Frogster. Comparing companies based on how many shares are on offer is a meaningless metric - it is like comparing companies purely based on SP and saying that a $100 company is somehow different (more expensive) from a $2 company. Need to look at both shares issued and SP together which is of course what market cap captures. Avita could do a 100:1 share consolidation to reduce the shares issued to 18.6 million, but of course the SP would increase 100 times to $49 - end result is no change to any of the fundamentals or the worth of the holdings anyone has.

Sorry you missed out on the SP watching fun today Frogster!
  Forum: By Share Code

Verharven
Posted on: May 16 2019, 02:46 PM


Group: Member
Posts: 851

A special milestone


Attached image(s)
Attached Image

 
  Forum: By Share Code

Verharven
Posted on: May 15 2019, 02:29 PM


Group: Member
Posts: 851

And noted that James no longer states that CUV is too expensive and here we have the SP up 6% as I write this. And 800,000 open short positions still come back into the market and just about all of them are well out of the money. Add in a good chance of ASX200 inclusion and the spike that will give from the ETF buying etc plus of course the little matter of the sub 60 days countdown to FDA decision and that potential run-up and it is a good time be a CUV holder.
  Forum: By Share Code

Verharven
Posted on: May 15 2019, 09:39 AM


Group: Member
Posts: 851

Clicking the link, I get a message that need to read it on a device that has Apple News?
  Forum: By Share Code

Verharven
Posted on: May 14 2019, 02:40 PM


Group: Member
Posts: 851

Yes, Nearmap was added about a month ago as an out of cycle inclusion when MYOB was removed due to a takeover. At the rebalance time in March, CUV and NEA were neck and neck for being next in line for inclusion. It will come down to liquidity for CUV as the final hurdle to clear.
  Forum: By Share Code

Verharven
Posted on: May 9 2019, 09:22 AM


Group: Member
Posts: 851

Shaping up to be a healthy start


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

Verharven
Posted on: May 8 2019, 08:48 AM


Group: Member
Posts: 851

Bank of New York Mellon now listed as a substantial shareholder with 5.2M shares so any clues what that this relates to in this now needing to be notified to the market? The announcement makes for great reading as page 6 onwards is about the original relationship between BNY as a ADR holder and Epitan way back in 2004 laugh.gif


Attached File(s)
Attached File  Announcements.pdf ( 1.81MB ) Number of downloads: 143

 
  Forum: By Share Code

Verharven
Posted on: May 7 2019, 04:25 PM


Group: Member
Posts: 851

On April 17 the SP closed at $24.40 and there were 419k short positions. Since then, the SP has dipped down into the low $20s and is now moving strongly back above that $24.40 mark but the number of short positions sits at almost double at 794k (as of last Wednesday) - that's a lot of shorts under water.
  Forum: By Share Code

Verharven
Posted on: May 5 2019, 01:41 PM


Group: Member
Posts: 851

Here's what happens when you don't take FDA's concern's about manufacturing seriously

https://endpts.com/fda-rejects-acacias-lead...acturing-issue/

FDA rejects Acacia’s lead drug — again — due to the same manufacturing issue

May 3, 2019

Acacia Pharma did well on the R&D front — by 2017, it had conducted four positive pivotal clinical trials for its lead drug, Barhemsys. Later that year, it submitted an FDA application to market the drug for rescue treatment of patients who develop postoperative nausea & vomiting (PONV), despite having been given prior antiemetic prophylaxis — only to receive a rejection in October 2018.

The US agency made its decision based on a pre-approval inspection of a facility run by the contract manufacturer of the drug’s main ingredient — amisulpride — and not on clinical or non-clinical data in the application, assured Acacia in a press release, adding that the FDA had asked for no extra studies or data analyses related to the treatment.

With renewed enthusiasm later that month, Acacia said its contract manufacturer had agreed to “institute a corrective and preventive action plan that will rectify the deficiency identified as quickly as possible. We continue to plan for a launch in the first half of 2019,” Acacia chief Julian Gilbert said in a statement.

Acacia then resubmitted its marketing application in December, indicating that the FDA’s concerns outlined in the complete response letter had been resolved. But on Friday, the company received another rejection, with the FDA flagging the same concerns.

“We are on track to complete the qualification of an alternative supplier of amisulpride and plan to engage with FDA as soon as possible to determine the most rapid route to obtaining approval,” Gilbert said in a statement on Friday.

Barhemsys is designed to help the 30-40% of surgical patients who suffer from PONV despite prior prophylaxis, as well as for combination prophylaxis in high-risk patients.

Cambridge, UK-based Acacia Pharma, which also has US operations in Indianapolis, was founded in 2007. It has another amisulpride-based drug — APD403 — in mid-stage development for chemotherapy induced nausea & vomiting.
  Forum: By Share Code

Verharven
Posted on: May 4 2019, 06:44 PM


Group: Member
Posts: 851

Just getting a handle on pure probabilities for the chance of approval for any drug once it gets to NDA submission. Data here from 2006-2015 covering 1,050 submissions puts the success rate at 85.3% taking into account re-submissions. Puts into context the ridiculous binary probablity PW used in the newsletter of 50-50 as that's like saying my chance of winning lotto tonight is 50-50 in that I either win or I don't when the true probability is several million to 1 against.

https://www.bio.org/sites/default/files/Cli...lion%202016.pdf
  Forum: By Share Code

Verharven
Posted on: May 3 2019, 07:39 AM


Group: Member
Posts: 851

Just hit 'Esc' or any other way to stop a page from fully loading and paywall problem solved
  Forum: By Share Code

Verharven
Posted on: May 2 2019, 06:10 AM


Group: Member
Posts: 851

Insto and fund ownership updated to April 30 (click on the ownership tab) https://www.morningstar.com/stocks/pinx/clvlf/quote.html

Fidelity is now out! Vanguard picked up all of their shares as they added ~948k over their various funds in the month of April (click on the 'Funds' and 'Institutions' tabs to see this)
  Forum: By Share Code

5 Pages (Click to Jump) V   1 2 3 4 > » 

Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING